Effects of CSL324 in the Lung After Segmental Challenge
Launched by CSL BEHRING · Dec 15, 2022
Trial Information
Current as of January 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female volunteer.
- • Between the ages of ≥ 18 and ≤ 65 years.
- • Body mass index within the range of 18 to 32 kg/m2
- • Female of nonchildbearing potential or of childbearing potential and willing to use a highly effective method of contraception (in addition to male partner condom with or without spermicide)
- • Nonsmoker or an ex-smoker who has stopped smoking (including e-cigarettes or vaping devices) for \> 1 year with a smoking history of \< 10 pack-years.
- Exclusion Criteria:
- • Any clinically significant abnormalities in physical examination findings, electrocardiogram (ECG) readings, safety laboratory test results, or ANC \< 2.0 × 109 cells/L.
- • History of myeloproliferative or lymphoproliferative disease.
- • Current or previous history of any immunosuppressive condition.
- • Currently receiving any immunosuppressive or immunomodulatory therapy, or history of undergoing such therapy.
Trial Officials
Study Director
Study Director
CSL Behring
About Csl Behring
CSL Behring is a global biotechnology leader focused on developing innovative therapies for patients with serious and rare diseases. As a subsidiary of CSL Limited, the company specializes in the research, development, and manufacture of life-saving biotherapies derived from human plasma. With a strong commitment to scientific excellence and patient care, CSL Behring conducts rigorous clinical trials to advance its portfolio of immunoglobulins, clotting factors, and other biopharmaceuticals. The organization aims to enhance the quality of life for patients worldwide while maintaining the highest standards of safety and efficacy in its products.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hannover, , Germany
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials